Understanding the PKAN Diagnosis: A Guide for Patients and Families
At a Glance
PKAN is a rare inherited disorder caused by changes in both copies of PANK2. MRI may show the eye-of-the-tiger pattern from iron buildup in the globus pallidus, but genetic testing usually confirms the diagnosis.
Receiving a diagnosis of Pantothenate Kinase-Associated Neurodegeneration (PKAN) is often the end of a long, confusing search for answers and the beginning of a new, complex journey. Whether you are an adult newly diagnosed or a parent, the path to this moment has often been marked by “clumsiness” that didn’t go away, unexplained falls, or stiff movements that doctors initially struggled to identify [1]. It is completely normal to feel a mix of grief, fear, and even a strange sense of relief that the condition finally has a name. You are not alone in this; while the disease is rare, there is a dedicated community of families and specialists ready to support you.
What PKAN Does Not Mean: This diagnosis is not caused by parenting, routine diet, or anything you or your family did. Because symptoms and progression vary widely even within the same family, your journey will be unique.
An Exceptionally Rare Condition
PKAN is a ultra-rare genetic disorder. It is part of a larger group of conditions called Neurodegeneration with Brain Iron Accumulation (NBIA), which all involve iron buildup in specific parts of the brain [2].
To put its rarity in perspective, researchers estimate that PKAN occurs in approximately 2 per million live births globally [3]. Because it is so uncommon, many local pediatricians or even general neurologists may have never encountered a case before. This rarity is often why families experience significant diagnostic delays—sometimes years—before reaching a specialist who recognizes the signs [4].
The Biological Mechanism: What is Happening?
PKAN is an inherited condition, meaning it is passed down through genes. It occurs when a person inherits two changed copies (mutations) of the PANK2 gene, one from each parent [5].
The PANK2 gene is responsible for making an enzyme called pantothenate kinase 2. This enzyme has a vital job: it starts the process of turning Vitamin B5 (pantothenate) into Coenzyme A (CoA) [6]. You can think of CoA as a specialized cofactor or “fuel” that the mitochondria (the power plants of your cells) need to function properly in many metabolic reactions [7].
When the PANK2 gene is mutated, the production of this “fuel” is disrupted. This leads to several problems inside the brain cells. While the exact chain of events is incompletely understood, researchers use this simplified model:
- Mitochondrial Dysfunction: The cell’s power plants cannot produce energy efficiently or manage fats correctly [8].
- Iron Accumulation: For reasons researchers are still studying, this metabolic breakdown causes iron to collect predominantly in a specific part of the brain called the globus pallidus [9].
- Cell Damage: The combination of poor energy production and excess iron is thought to lead to oxidative stress—a type of internal “rusting” that eventually damages and destroys nerve cells [10][11].
Note: Because this is a complex genetic disruption, over-the-counter high-dose Vitamin B5 or other supplements have not been proven to treat PKAN and should not be started without the guidance of your care team.
Understanding the “Eye of the Tiger”
The globus pallidus is a small structure deep in the brain that helps control smooth, coordinated movement. When iron builds up there, it creates a very specific pattern on an MRI (Magnetic Resonance Imaging) scan.
Doctors call this the “eye of the tiger” sign. On certain MRI views, the iron makes the globus pallidus look very dark, but a small spot in the center remains bright because of cell damage and fluid buildup [12]. While this sign is found in about 95% of children with the “classic” early-onset form of PKAN, it is not always present in the very early stages of the disease or in “atypical” cases that begin later in life [13][1].
If your doctor mentions this sign, it is a strong indicator of PKAN, but a definitive diagnosis is usually confirmed through genetic testing to find the specific PANK2 mutations [14][15].
Navigating the Emotional Impact
The transition from “searching for a diagnosis” to “managing a rare disease” is a major life event. It is common for individuals to feel overwhelmed by the technical language and the uncertainty of the future.
Expert consensus emphasizes that because PKAN affects everyone differently, the journey will be unique [16]. Connecting with specialized NBIA centers of excellence and patient advocacy groups can provide not only the most current medical information but also a community that understands the day-to-day reality of living with PKAN [17]. Your care team’s goal now is to move from diagnosis to a proactive plan that focuses on comfort, communication, and quality of life.
Common questions in this guide
What causes PKAN?
What does the eye-of-the-tiger sign mean on an MRI?
How is PKAN confirmed?
Can vitamin B5 supplements treat PKAN?
Is PKAN inherited, and could it affect other family members?
Which specialists should be involved after a PKAN diagnosis?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Pantothenate kinase-associated neurodegeneration.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specifically in the genetic report confirms the diagnosis of PKAN for me or my child?
- 2.Can you walk us through the MRI findings and explain if you see the 'eye of the tiger' pattern or other signs of iron buildup?
- 3.How much experience does this hospital or care team have with PKAN or other NBIA disorders?
- 4.Which specialists, such as a movement disorder neurologist or a genetic counselor, should we see next?
- 5.Are there specific multidisciplinary clinics or centers of excellence for PKAN you can refer us to?
References
References (17)
- 1
Brain MRI Pattern Recognition in Neurodegeneration With Brain Iron Accumulation.
Lee JH, Yun JY, Gregory A, et al.
Frontiers in neurology 2020; (11()):1024 doi:10.3389/fneur.2020.01024.
PMID: 33013674 - 2
Metabolic impairments in neurodegeneration with brain iron accumulation.
Wydrych A, Pakuła B, Janikiewicz J, et al.
Biochimica et biophysica acta. Bioenergetics 2025; (1866(1)):149517 doi:10.1016/j.bbabio.2024.149517.
PMID: 39366438 - 3
Incidence of PKAN determined by bioinformatic and population-based analysis of ~140,000 humans.
Brezavar D, Bonnen PE
Molecular genetics and metabolism 2019; (128(4)):463-469 doi:10.1016/j.ymgme.2019.09.002.
PMID: 31540697 - 4
Mitochondrial Membrane Protein-Associated Neurodegeneration Mimicking Juvenile Amyotrophic Lateral Sclerosis.
Kim J, Liao YH, Ionita C, et al.
Pediatric neurology 2016; (64()):83-86 doi:10.1016/j.pediatrneurol.2016.08.013.
PMID: 27671242 - 5
Inborn errors of coenzyme A metabolism and neurodegeneration.
Di Meo I, Carecchio M, Tiranti V
Journal of inherited metabolic disease 2019; (42(1)):49-56 doi:10.1002/jimd.12026.
PMID: 30740736 - 6
A Potential Citrate Shunt in Erythrocytes of PKAN Patients Caused by Mutations in Pantothenate Kinase 2.
Werning M, Dobretzberger V, Brenner M, et al.
Biomolecules 2022; (12(2)) doi:10.3390/biom12020325.
PMID: 35204826 - 7
From Common Pathway to Divergent Diseases: Metabolic Aspects of Inborn Errors of CoA Biosynthesis.
Di Meo I, Anikster Y, Tiranti V, Iuso A
Journal of inherited metabolic disease 2026; (49(5)):e70239 doi:10.1002/jimd.70239.
PMID: 42601840 - 8
4'-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN.
Jeong SY, Hogarth P, Placzek A, et al.
EMBO molecular medicine 2019; (11(12)):e10489 doi:10.15252/emmm.201910489.
PMID: 31660701 - 9
Mitochondrial iron deficiency triggers cytosolic iron overload in PKAN hiPS-derived astrocytes.
Santambrogio P, Cozzi A, Balestrucci C, et al.
Cell death & disease 2024; (15(5)):361 doi:10.1038/s41419-024-06757-9.
PMID: 38796462 - 10
Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration.
Orellana DI, Santambrogio P, Rubio A, et al.
EMBO molecular medicine 2016; (8(10)):1197-1211 doi:10.15252/emmm.201606391.
PMID: 27516453 - 11
Mitochondrial and autophagic dysfunctions of skin fibroblasts derived from pantothenate kinase-associated neurodegeneration patients carrying PANK2 mutations and the rescuing effects of allantoin.
Zhu J, Yao T, Wang C
Parkinsonism & related disorders 2025; (134()):107806 doi:10.1016/j.parkreldis.2025.107806.
PMID: 40138891 - 12
A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study.
Pereira A, Fischinger Moura de Souza C, Álvarez-Córdoba M, et al.
Orphanet journal of rare diseases 2024; (19(1)):442 doi:10.1186/s13023-024-03453-x.
PMID: 39609877 - 13
Clinical, imaging and genetic profile of twenty-four patients with pantothenate kinase-associated neurodegeneration (PKAN)- A single centre study from India.
Sriram N, Holla VV, Kumari R, et al.
Parkinsonism & related disorders 2023; (111()):105409 doi:10.1016/j.parkreldis.2023.105409.
PMID: 37121191 - 14
Novel PANK2 mutation discovered among South East Asian children living in Thailand affected with pantothenate kinase associated neurodegeneration.
Sakpichaisakul K, Saengow VE, Suwanpratheep P, et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2019; (66()):187-190 doi:10.1016/j.jocn.2019.04.017.
PMID: 31088771 - 15
Clinically Suspected Atypical Pantothenate Kinase-Associated Neurodegeneration Without the Eye-of-the-Tiger Sign: A Case Report.
Rode R, Salunkhe P, Madavi J, Virdande P
Cureus 2026; (18(7)):e113136 doi:10.7759/cureus.113136.
PMID: 42630559 - 16
CLINICAL EFFECT OF A MUTATION (p.Glu322Asp, c.966 G>T) IN PANK2 GENE IN A FAMILY WITH ATYPICAL PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION.
Ayas ZO, Karkucak M, Ocal RO, Yakut T
Genetic counseling (Geneva, Switzerland) 2016; (27(4)):489-494.
PMID: 30226968 - 17
Treatment of Pantothenate-Kinase Neurodegeneration With Baclofen, Botulinum Toxin, and Deferiprone: A Case Report.
Hameed M, Siddiqui F, Khan MK, et al.
Brain & NeuroRehabilitation 2023; (16(3)):e25 doi:10.12786/bn.2023.16.e25.
PMID: 38047104
This page explains PKAN diagnosis, MRI findings, and PANK2 genetic testing for informational purposes only and does not constitute medical advice. Your neurologist, genetics team, and other specialists should interpret your or your child's results and plan care.